Table 1.
Baseline clinicopathological characteristics of patients with APC.
| Valuables | Category | Characteristics |
|---|---|---|
| Gender | Male | 92 (64.8%) |
| Female | 50 (35.2%) | |
| Age | Median (Range) | 61 (34–86) |
| ECOG PS | 0 | 14 (9.9%) |
| 1 | 108 (76.1%) | |
| 2 | 20 (14.1%) | |
| Primary tumor location | Head and neck | 61 (43.0%) |
| Body and tail | 81 (57.0%) | |
| TNM stage | III | 41 (28.9%) |
| IV | 101 (71.1%) | |
| Liver metastasis | Yes | 71 (50.0%) |
| No | 71 (50.0%) | |
| Chemotherapy | Gemcitabine monotherapy | 50 (35.2%) |
| Gemcitabine combination therapy | 45 (31.7%) | |
| Gemcitabine exclusive therapy | 47 (33.1%) | |
| Albumin (g/L) | Median (Range) | 39.2 (26.1–48.4) |
| CRP (mg/L) | Median (Range) | 3.55 (0.2–178.0) |
| CAR | Median (Range) | 0.099 (0.004–5.266) |
| GPS | 0 | 79 (55.6%) |
| 1 | 47 (33.1%) | |
| 2 | 16 (11.3%) | |
| mGPS | 0 | 92 (64.8%) |
| 1 | 34 (23.9%) | |
| 2 | 16 (11.3%) | |
| AST (IU/L) | Median (Range) | 25.0 (7.3–1529.0) |
| ALT (IU/L) | Median (Range) | 20.9 (5.0–1300.0) |
| CA19–9 (U/ml) | Median (Range) | 430.45 (0.60–2084.00) |
| CEA (ng/ml) | Median (Range) | 6.57 (0.40–1065.00) |
| Hemoglobin (g/L) | Median (Range) | 122 (75–168) |